<DOC>
	<DOCNO>NCT00233012</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics safety tolerability topiramate infant age 1-24 month refractory partial-onset seizure . Topiramate antiepileptic drug approve use adult pediatric patient ( age 2 16 year ) refractory partial onset seizure ( POS ) without secondarily generalize seizure , primary generalize tonic clonic seizure , Lennox-Gastaut syndrome ( LGS ) .</brief_summary>
	<brief_title>A Study Pharmacokinetics , Safety Tolerability Topiramate Infants ( Age 1-24 Months ) With Refractory Partial-onset Seizures</brief_title>
	<detailed_description>This open-label , randomize ( patient assign different treatment base chance ) , dose comparison , multicenter study topiramate infant age 1-24 month refractory partial-onset seizure ( POS ) . The trial evaluate pharmacokinetics , safety , tolerability topiramate use additional treatment infant refractory POS . Topiramate administer liquid sprinkle adjunct ( additional treatment ) concurrent anticonvulsant therapy . The study consist 4 phase : pretreatment phase include screening ( 7 day ) baseline ( 1 day ) , open-label treatment phase ( 6 week ) , open-label extension phase ( 54 week ) , posttreatment phase ( 4 week ) . Seizure diary maintain throughout study patient ' parent , legally acceptable representative , caregiver . In open-label treatment phase , patient randomly assign 1 4 treatment : topiramate 3 , 5 , 15 , 25 mg/kg per day . Venous blood sample ( four 1 milliliter [ mL ] sample ) collect 2 day study determine plasma concentration topiramate . Safety evaluate throughout study monitor adverse event result clinical laboratory test ( serum chemistry , venous ammonia , hematology , urinalysis ) , electrocardiogram ( ECGs ) , vital sign measurement ( pulse blood pressure ) , physical examination , neurologic examination , Vineland Scales Adaptive Behavior , renal ultrasound , assessment adequate food liquid intake , hyperthermia , oligohydrosis , rash , take-home record . Liquid sprinkle form topiramate , 3,5,15 , 25mg/kg per day 54 week .</detailed_description>
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<criteria>Regular enteral feeding ( solid food bottle cupfed ) without breastfeed weigh &gt; /=3.5 kilogram ( kg ) &lt; 15.5 kg Length use infant measuring table ( heel crown ) must = 49 cm clinical electroencephalographic ( EEG ) evidence POS ( simple complex ) without secondary generalization least 1 month duration infant &gt; 6 month age , least 2 week duration infant &lt; 6 month age Multiple seizure type allow long POS present Taking 1 2 concurrent market antiepileptic drug ( AEDs ) &gt; 1 month infant &gt; 6 month age &gt; 2 week infant &lt; 6 month age regimen AEDs entry must consider inadequate controlling seizure , optimized opinion investigator Have computerize tomography magnetic resonance image scan confirm absence progressive lesion tumor , exception lesion tuberous sclerosis SturgeWeber syndrome , allow . Exclusively breastfed take oral liquid medication Receives regular enteral feeding use gastrostomy , jejunostomy , nasogastric tube surgically implant function vagus nerve stimulator Have febrile seizure seizure due acute medical illness Have infantile seizure result correctable medical condition metabolic disturbance , toxic exposure , neoplasm , active infection History nonepileptic seizure , either current point past Any progressive neurologic disorder , include malignancy , brain tumor , active central nervous system infection , demyelinate disease , degenerative progressive central nervous system disease exception tuberous sclerosis Sturge Weber syndrome .</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Refractory partial-onset seizure</keyword>
	<keyword>Infants age 1-24 month</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Topiramate</keyword>
</DOC>